Myelodysplastic syndrome and acute myeloid leukemia after autotransplantation for lymphoma: A multicenter case-control study

Blood

Volumn 101, Issue 5, 2003, Pages 2015-2023

  Metayer, Catherine ^b   Curtis, Rochelle E ^a   Vose, Julie ^b   Sobocinski, Kathleen A ^b   Horowitz, Mary M ^b   Bhatia, Smita ^b   Fay, Joseph W ^b   Freytes, Cesar O ^b   Goldstein, Steven C ^b   Herzig, Roger H ^b   Keating, Armand ^b   Miller, Carol B ^b   Nevill, Thomas J ^b   Pecora, Andrew L ^b   Rizzo, Douglas J ^b   Williams, Stephanie F ^b   Li, Chin Yang ^b   Travis, Lois B ^b   Weisdorf, Daniel J ^b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; CARMUSTINE; CHLORAMBUCIL; CHLORMETHINE; CISPLATIN; CYCLOPHOSPHAMIDE; EPIPODOPHYLLOTOXIN; ETOPOSIDE; GYRASE INHIBITOR; MELPHALAN; PREDNISONE; PROCARBAZINE; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; AUTOTRANSPLANTATION; BONE MARROW TRANSPLANTATION; CANCER CHEMOTHERAPY; CASE CONTROL STUDY; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HODGKIN DISEASE; HUMAN; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYELODYSPLASTIC SYNDROME; NONHODGKIN LYMPHOMA; PERIPHERAL BLOOD STEM CELL; PRIORITY JOURNAL; RADIATION DOSE; RISK FACTOR; WHOLE BODY RADIATION;

EID: 0037370887     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2002-04-1261     Document Type: Article

References (51)

1. Miller JS, Arthur DC, Litz CE, et al. Myelodysplastic syndrome after autologous bone marrow transplantation: an additional late complication of curative cancer therapy [see comments]. Blood. 1994;83:3780-3786.
2. Traweek ST, Slovak ML, NademaneeAP, Brynes RK, Niland JC, Forman SJ. Clonal karyotypic hematopoietic cell abnormalities occurring after autologous bone marrow transplantation for Hodgkin's disease and non-Hodgkin's lymphoma. Blood. 1994;84:957-963.
3. Darrington DL, Vose JM, Anderson JR, et al. Incidence and characterization of secondary myelodysplastic syndrome and acute myelogenous leukemia following high-dose chemoradiotherapy and autologous stem-cell transplantation for lymphoid malignancies. J Clin Oncol. 1994;12:2527-2534.
4. Stone RM, Neuberg D, Soiffer R, et al. Myelodysplastic syndrome as a late complication following autologous bone marrow transplantation for non-Hodgkin's lymphoma. J Clin Oncol. 1994;12:2535-2542.
5. Bhatia S, Ramsay NK, Steinbuch M, et al. Malignant neoplasms following bone marrow transplantation. Blood. 1996;87:3633-3639.
6. Pedersen-Bjergaard J, Pedersen M, Myhre J, Geisler C. High risk of therapy-related leukemia after BEAM chemotherapy and autologous stem cell transplantation for previously treated lymphomas is mainly related to primary chemotherapy and not to the BEAM-transplantation procedure. Leukemia. 1997;11:1654-1660.
7. André M, Henry-Amar M, Blaise D, et al. Treatment-related deaths and second cancer risk after autologous stem-cell transplantation for Hodgkin's disease. Blood. 1998;92:1933-1940.
8. Friedberg JW, Neuberg D, Stone RM, et al. Outcome in patients with myelodysplastic syndrome after autologous bone marrow transplantation for non-Hodgkin's lymphoma. J Clin Oncol. 1999;17:3128-3135.
9. Harrison CN, Gregory W, Hudson GV, et al. High-dose BEAM chemotherapy with autologous haemopoietic stem cell transplantation for Hodgkin's disease is unlikely to be associated with a major increased risk of secondary MDS/AML. Br J Cancer. 1999;81:476-483.
10. Milligan DW, Ruiz De Elvira MC, Kolb HJ, et al. Secondary leukaemia and myelodysplasia after autografting for lymphoma: results from the EBMT. EBMT Lymphoma and Late Effects Working Parties. European Group for Blood and Marrow Transplantation. Br J Haematol. 1999;106:1020-1026.
11. Krishnan A, Bhatia S, Slovak ML, et al. Predictors of therapy-related leukemia and myelodysplasia following autologous transplantation for lymphoma: an assessment of risk factors. Blood. 2000;95:1588-1593.
12. Pedersen-Bjergaard J, Andersen MK, Christiansen DH. Therapy-related acute myeloid leukemia and myelodysplasia after high-dose chemotherapy and autologous stem cell transplantation. Blood. 2000;95:3273-3279.
13. Micallef INM, Lillington DM, Apostolidis J, et al. Therapy-related myelodysplasia and secondary acute myelogenous leukemia after high-dose therapy with autologous hematopoietic progenitor-cell support for lymphoid malignancies. J Clin Oncol. 2000;18:947-955.
14. Longo DL, Duffey PL, Young RC, et al. Conventional dose salvage combination chemotherapy in patients relapsing with Hodgkin's disease after combination chemotherapy: the low probability for cure. J Clin Oncol. 1992;10:210-218.
15. Linch DC, Winfield D, Goldstone AH, et al. Dose intensification with autologous bone marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomized trial. Lancet. 1993;341:1051-1054.
16. Rohatiner AZ, Johnson PWM, Price CGA, et al. Myeloablative therapy with autologous bone marrow transplantation as consolidation therapy for recurrent follicular lymphoma. J Clin Oncol. 1994;12:1177-1184.
17. Philip T, Guglielmi C, Hagenbeek A, et al. Autologous bone marrow transplantation as compared to salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med. 1995;333:1540-1545.
18. Del Canizo C, Amigo L, Hernandez J, et al. Incidence and characterization of secondary myelodysplastic syndromes following autologous transplantation. Haematologica. 2000;85:403-409.
19. Kaldor JM, Day NE, Clarke EA, et al. Leukemia following Hodgkin's disease [see comments]. N Engl J Med. 1990;322;7-13.
20. Travis LB, Curtis RE, Stovall M, et al. Risk of leukemia following treatment for non-Hodgkin's lymphoma. J Natl Cancer Inst. 1994;86:1450-1457.
21. van Leeuwen FE, Chorus AM, van den Belt-Dusebout AW, et al. Leukemia risk following Hodgkin's disease: relation to cumulative dose of alkylating agents, treatment with teniposide combinations, number of episodes of chemotherapy, and bone marrow damage. J Clin Oncol. 1994;12:1063-1073.
22. van Leeuwen FE, Travis LB. Second cancers. In: DeVita VT Jr, Hellman S, Rosenberg SA, eds. Cancer: Principles and Practices of Oncology. Vol 2. 6th ed. Philadelphia, PA: Lippincott-Raven; 2001:76-80.
23. van der Velden JW, van Putten WL, Guinee VF, et al. Subsequent development of acute non-lymphocytic leukemia in patients treated for Hodgkin's disease, Int J Cancer. 1988;42:252-255.
24. Andrieu JM, Ifrah N, Payen C, Fermanian J, Coscas Y, Flandrin G. Increased risk of secondary acute nonlymphocytic leukemia after extended-field radiation therapy combined with MOPP chemotherapy for Hodgkin's disease [see comments]. J Clin Oncol. 1990;8:1148-1154.
25. Sureda A, Arranz R, Iriondo A, et al. Autologous stem-cell transplantation for Hodgkin's disease: results and prognostic factors in 494 patients from the Grupo Español de Linfomas/Transplante Autólogo de Médula Ósea Spanish Cooperative Group, J Clin Oncol. 2001;19:1395-1404.
26. Stovall M, Smith SA, Rosenstein M. Tissue doses from radiotherapy of cancer of the uterine cervix. Med Phys. 1989;16:726-733.
27. Breslow NE, Day NE. Statistical methods in cancer research. The analysis of case-control studies. Vol 1. Lyon, France: International Agency for Research on Cancer, 1980. IARC scientific publication no. 32.
28. SAS Institute. SAS user's guide: Statistics (8.0). Cary, NC:SAS Institute; 1999.
29. Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med. 1999;18:695-706.
30. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
31. Kaldor JM, Day NE, Pettersson F, et al. Leukemia following chemotherapy for ovarian cancer [see comments]. N Engl J Med. 1990;322:1-6.
32. Greene MH, Young RC, Merrill JM, DeVita VT. Evidence of a treatment dose response in acute nonlymphocytic leukemias which occur after therapy of non-Hodgkin's lymphoma. Cancer Res. 1983;43:1891-1898.
33. Greene MH, Harris EL, Gershenson DM, et al. Melphalan may be a more potent leukemogen than cyclophosphamide, Ann Intern Med. 1986;105:360-367.
34. Curtis RE, Boice JD Jr, Stovall M, et al. Risk of leukemia after chemotherapy and radiation treatment for breast cancer. N Engl J Med. 1992;326:1745-1751.
35. International Agency for Research on Cancer. IARC monographs on the evaluation of carcinogenic risks to humans, pharmaceutical drugs. Vol 50. Lyon, France: IARC; 1989.
36. Bennett JM, Catovsky D, Daniel MT, et al. Proposal for the classification of myelodysplastic syndromes. Br J Hematol. 1982;51:189-199.
37. Harris N, Jaffe E, Diebold J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting - Airlie House, Virginia, November 1997. J Clin Oncol. 1999;17:3835-3849.
38. Bennett JM, Catovsky D, Daniel MT, et al. Proposed revised criteria for the classification of acute myeloid leukemia. Ann Intern Med, 1985;103:626-629.
39. Boivin JF, Hutchinson GB, Zauber AG, et al. Incidence of second cancers in patients treated for Hodgkin's disease. J Natl Cancer Inst, 1995;87:732-741.
40. Travis LB, Holowaty EJ, Bergfeldt K, et al. Risk of leukemia after platinum-based chemotherapy for ovarian cancer, N Engl J Med. 1999;340:351-357.
41. Boice JD Jr, Greene MH, Killen JY, et al. Leukemia after adjuvant chemotherapy with semustine (methyl-CCNU) - evidence of a dose-response effect. N Engl J Med. 1986;314:119-120.
42. Travis LB, Andersson M, Gospodarowicz M, et al. Treatment-associated leukemia following testicular cancer. J Natl Cancer Inst. 2000;92:1165-1171.
43. Pui CH, Ribeiro RC, Hancock ML, et al. Acute myeloid leukemia in children treated with epipodophyllotoxins for acute lymphoblastic leukemia. N Engl J Med. 1991;325:1682-1687.
44. Pui CH, Relling MV, Rivera GK, et al. Epipodophyllotoxin-related acute myeloid leukemia: a study of 35 cases. Leukemia. 1995;9:1990-1996.
45. Winick NJ, McKenna RW, Shuster JJ, et al. Secondary acute myeloid leukemia in children with acute lymphoblastic leukemia treated with etoposide [see comments]. J Clin Oncol. 1993;11:209-217.
46. Koilmannsberger C, Beyer J, Droz JP, et al. Secondary leukemia following high cumulative doses of etoposide in patients treated for advanced germ cell tumors. J Clin Oncol. 1998;16:3386-3391.
47. Mach-Pascual S, Legare RD, Lu D, et al. Predictive value of clonality assays in patients with non-Hodgkin's lymphoma undergoing autologous bone marrow transplant: a single-institution study. Blood. 1998;91:4496-4503.
48. Abruzzese E, Radford JE, Miller JS, et al. Detection of abnormal pretransplant clones in progenitor cells of patients who developed myelodysplasia after autologous transplantation. Blood. 1999;94:1814-1819.
49. Lillington DM, Micaleft INM, Carpenter E, et al. Detection of chromosome abnormalities pre-high-dose treatment in patients developing therapy-related myelodysplasia and second acute myelogenous leukemia after treatment for non-Hodgkin's lymphoma. J Clin Oncol. 2001;19:2472-2481.
50. Deeg HJ, Socié G. Malignancies after hemotopoietic stem cell transplantation: many questions, some answers. Blood. 1998;91:1833-1843.
51. Maillie H, Baker J, Simon W, Watts RJ, Quinn BR. Age related rejoining of broken chromosomes in human leukocytes following X-irradiation. Mech Ageing Dev. 1992;65:229-238.